Arialytics is a quantitative investment research firm. We are developing advanced cognitive and quantitative technologies that support portfolio construction and the development of professional investment strategies.
Scientific Research and Portfolio Construction
Our aim is to develop superior portfolio solutions that maximize outcomes and minimize return distribution uncertainty through the discovery of novel strategies, empirically proven over market cycles. Central to our research approach is a deep commitment to eliminating analytic bias with rigorous scientific methods.
Novel Investment Strategies
We focus on discovering novel investment strategies that seek to achieve desired outcomes. We work with professional investment organizations including registered investment companies, pension funds, sovereign wealth funds, endowments and family offices.
Systematic Investment Management
We’re at the forefront of harnessing new tools including advanced econometrics, artificial intelligence, big data, and dynamic prediction to amplify our research capabilities and enhance their scientific validity. These and other technologies help us identify risks and extract investable insight from noisy market data and changing market conditions.
David is the Managing Director of Arialytics and leads our research initiatives. Arialytics was founded in 2010 in response to growing demand in the professional investment community for sophisticated quantitative investment and trading strategies that are based on scientifically and empirically valid research methods and, increasingly, machine cognition.
David has nearly three decades of experience in research and advisory leadership roles. Prior to Arialytics, he was a Principal at The Boston Consulting Group (BCG), where he advised executives at some of the worlds leading asset management and pharmaceutical firms, and Founder and CEO of an artificial intelligence venture overseeing over 40 researchers and employees.
David has extensive experience developing and managing comlex, systematic long/short and long-only multi-asset-class, multi-strategy solutions. He has also done pioneering work in the development of methodologies to predict drug trial outcomes and future prices of high-tech goods.
David holds an MBA degree from the University of Chicago, Booth School of Business where he was a Sara Lee Fellowship recipient and was fortunate to have had three lecturers who have received the Nobel Prize in Economics. He holds a BA degree in Economics, magna cum laude, from SUNY Buffalo where he was an Honors Scholar.
Send an email to David: